Paradigm Capital Management Inc. NY Makes New $39.77 Million Investment in DENTSPLY SIRONA Inc. $XRAY

Key Points

• Paradigm Capital Management initiated a $39.8 million position in DENTSPLY SIRONA, purchasing 3.75 million shares and acquiring approximately 1.88% of the company. Institutional investors collectively own 95.7% of the stock.
• DENTSPLY SIRONA’s latest quarterly results exceeded expectations, with earnings of $0.52 per share versus the $0.35 consensus estimate and revenue of $898 million. However, revenue declined 4.1% year over year, and the company maintains full-year 2026 EPS guidance of $1.40–$1.50.
• XRAY shares opened at $10.89, below the 50-day and 200-day moving averages. Analysts remain broadly neutral, with a consensus “Hold” rating and an average price target of $13.54.

Paradigm Capital Management Inc. NY bought a new position in shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 3,748,800 shares of the medical instruments supplier's stock, valued at approximately $39,775,000. DENTSPLY SIRONA comprises 1.1% of Paradigm Capital Management Inc. NY's investment portfolio, making the stock its 21st largest position. Paradigm Capital Management Inc. NY owned 1.88% of DENTSPLY SIRONA at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in DENTSPLY SIRONA during the 1st quarter worth about $26,000. Eurizon Capital SGR S.p.A. bought a new stake in shares of DENTSPLY SIRONA during the fourth quarter valued at approximately $26,000. Caitong International Asset Management Co. Ltd increased its holdings in shares of DENTSPLY SIRONA by 337.9% in the third quarter. Caitong International Asset Management Co. Ltd now owns 2,750 shares of the medical instruments supplier's stock valued at $35,000 after purchasing an additional 2,122 shares in the last quarter. Farther Finance Advisors LLC raised its position in DENTSPLY SIRONA by 119.1% in the 4th quarter. Farther Finance Advisors LLC now owns 3,773 shares of the medical instruments supplier's stock worth $43,000 after purchasing an additional 2,051 shares during the last quarter. Finally, Performa Ltd US LLC raised its position in DENTSPLY SIRONA by 116.1% in the 4th quarter. Performa Ltd US LLC now owns 4,250 shares of the medical instruments supplier's stock worth $49,000 after purchasing an additional 2,283 shares during the last quarter. 95.70% of the stock is owned by institutional investors.

Insider Buying and Selling at DENTSPLY SIRONA

In other news, Director Brian T. Gladden bought 9,985 shares of the stock in a transaction on Monday, June 15th. The stock was purchased at an average price of $10.02 per share, with a total value of $100,049.70. Following the completion of the purchase, the director owned 61,849 shares of the company's stock, valued at approximately $619,726.98. This trade represents a 19.25% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Brian P. Mckeon bought 10,000 shares of the business's stock in a transaction on Friday, June 12th. The stock was purchased at an average price of $10.12 per share, for a total transaction of $101,200.00. Following the completion of the acquisition, the director owned 10,000 shares of the company's stock, valued at approximately $101,200. This trade represents a ∞ increase in their position. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders bought 35,160 shares of company stock valued at $351,179. Corporate insiders own 0.46% of the company's stock.

DENTSPLY SIRONA Stock Down 0.3%

Shares of DENTSPLY SIRONA stock opened at $10.89 on Tuesday. The business has a fifty day simple moving average of $12.04 and a 200 day simple moving average of $11.79. The stock has a market cap of $2.17 billion, a PE ratio of -3.96, a price-to-earnings-growth ratio of 1.38 and a beta of 0.85. The company has a quick ratio of 1.07, a current ratio of 1.63 and a debt-to-equity ratio of 1.48. DENTSPLY SIRONA Inc. has a 12 month low of $9.40 and a 12 month high of $14.86.

DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) last released its earnings results on Thursday, August 6th. The medical instruments supplier reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.35 by $0.17. The firm had revenue of $898.00 million for the quarter, compared to analyst estimates of $889.93 million. DENTSPLY SIRONA had a positive return on equity of 20.84% and a negative net margin of 14.99%.The company's quarterly revenue was down 4.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.52 earnings per share. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Research analysts predict that DENTSPLY SIRONA Inc. will post 1.41 EPS for the current year.

Analyst Ratings Changes

XRAY has been the topic of a number of recent research reports. Piper Sandler increased their price objective on DENTSPLY SIRONA from $13.00 to $14.00 and gave the company a "neutral" rating in a research report on Wednesday, July 29th. BMO Capital Markets restated a "market perform" rating and set a $13.00 target price on shares of DENTSPLY SIRONA in a research report on Friday, August 7th. Barrington Research set a $15.00 price target on DENTSPLY SIRONA in a report on Monday, August 10th. UBS Group dropped their price objective on DENTSPLY SIRONA from $18.00 to $17.00 and set a "buy" rating for the company in a report on Thursday, May 7th. Finally, Mizuho reduced their target price on shares of DENTSPLY SIRONA from $16.00 to $14.00 and set a "neutral" rating on the stock in a research note on Wednesday, May 6th. Three equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have issued a Sell rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $13.54.

DENTSPLY SIRONA Profile

Dentsply Sirona Inc NASDAQ: XRAY is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company's product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source